Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HSCT for NMOSD
NCT03829566Phase 3Withdrawn
- Sponsor
- Northwestern University
- Start
- Nov 2019
- Primary completion
- Jan 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of autologous hematopoietic stem cells in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Northwestern University. Primary endpoint: Progression-Free Survival at 5 years. Planned start Nov 2019; status: withdrawn.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT03829566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829566.